A NOVEL CYP2D6 ALLELE WITH AN ABOLISHED SPLICE RECOGNITION SITE ASSOCIATED WITH THE POOR METABOLIZER PHENOTYPE

被引:44
作者
MAREZ, D
SABBAGH, N
LEGRAND, M
LOGUIDICE, JM
BOONE, P
BROLY, F
机构
[1] Laboratoire de Biochimie et Biologie Moléculaire de l’Hôpital Calmette, Centre Hospitalier Régional et Universitaire de Lille, Lille, 59037, Bd. J. Leclercq
来源
PHARMACOGENETICS | 1995年 / 5卷 / 05期
关键词
CYP2D6; PCR-SSCP; PHARMACOGENETIC; DEBRISOQUINE; GENOTYPING;
D O I
10.1097/00008571-199510000-00006
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
A novel loss-of function allele of the CYP2D6 gene was characterized in a PM individual using exon-by-exon PCR-SSCP analysis. This allele, we termed CYP2D6(F), harbours four mutations including a new mutation (D6-F) which abolishes the splice acceptor site of the Ist intron and results in a premature stop codon, DNA samples from a large population of healthy unrelated volunteers were tested for D6-F using a PCR-assay we developed for the specific identification of the mutation in genomic DNA. The prevalence of D6-F was very low. However, its identification combined with that of the previously reported gene inactivating mutations would further increase the phenotype prediction rate by genotyping.
引用
收藏
页码:305 / 311
页数:7
相关论文
共 32 条
[31]   DEBRISOQUINE AND MEPHENYTOIN OXIDATION IN SINHALESE - A POPULATION STUDY [J].
WEERASURIYA, K ;
JAYAKODY, RL ;
SMITH, CAD ;
WOLF, CR ;
TUCKER, GT ;
LENNARD, MS .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 38 (05) :466-470
[32]   RELATIONSHIP BETWEEN THE DEBRISOQUINE HYDROXYLASE POLYMORPHISM AND CANCER SUSCEPTIBILITY [J].
WOLF, CR ;
SMITH, CAD ;
GOUGH, AC ;
MOSS, JE ;
VALLIS, KA ;
HOWARD, G ;
CAREY, FJ ;
MILLS, K ;
MCNEE, W ;
CARMICHAEL, J ;
SPURR, NK .
CARCINOGENESIS, 1992, 13 (06) :1035-1038